| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SPRY1 |
| Uniprot No | O43609 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-319aa |
| 氨基酸序列 | MDPQNQHGSG SSLVVIQQPS LDSRQRLDYE REIQPTAILS LDQIKAIRGS NEYTEGPSVV KRPAPRTAPR QEKHERTHEI IPINVNNNYE HRHTSHLGHA VLPSNARGPI LSRSTSTGSA ASSGSNSSAS SEQGLLGRSP PTRPVPGHRS ERAIRTQPKQ LIVDDLKGSL KEDLTQHKFI CEQCGKCKCG ECTAPRTLPS CLACNRQCLC SAESMVEYGT CMCLVKGIFY HCSNDDEGDS YSDNPCSCSQ SHCCSRYLCM GAMSLFLPCL LCYPPAKGCL KLCRRCYDWI HRPGCRCKNS NTVYCKLESC PSRGQGKPS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SPRY1重组蛋白的模拟参考文献示例(非真实文献，仅供格式参考)：
1. **《Functional characterization of recombinant SPRY1 in RTK signaling modulation》**
- Zhang L. et al.
- 摘要：研究通过大肠杆菌表达系统成功纯化重组SPRY1蛋白，发现其可抑制FGF受体介导的MAPK通路激活，提示其在调控生长因子信号中的潜在作用。
2. **《Structural analysis of SPRY1 domain and its interaction with Cbl protein》**
- Wang Y. et al.
- 摘要：利用X射线晶体学解析重组SPRY1蛋白结构，揭示其与E3泛素连接酶Cbl的结合界面，为阐明SPRY1在蛋白质降解调控中的机制提供结构基础。
3. **《Recombinant SPRY1 attenuates pulmonary fibrosis in murine models》**
- Johnson R.B. et al.
- 摘要：在体实验表明，外源性重组SPRY1蛋白通过抑制TGF-β/Smad通路减轻小鼠肺纤维化病变，提示其作为治疗纤维化疾病的潜在生物制剂。
4. **《SPRY1 recombinant protein inhibits angiogenesis in vitro》**
- Chen H. & Li X.
- 摘要：体外实验证实重组SPRY1可抑制血管内皮细胞迁移和管腔形成，机制可能与竞争性结合VEGFR2胞内域并阻断其磷酸化有关。
(注：以上文献为模拟生成，实际研究中请通过PubMed/Google Scholar等平台检索真实文献。)
**Background of SPRY1 Recombinant Protein**
The SPRY domain-containing protein 1 (SPRY1) belongs to the SPRY protein family, characterized by a conserved SPRY domain implicated in protein-protein interactions and signaling regulation. Initially identified through homology to the *Drosophila* "SPRY" gene, SPRY1 is involved in modulating receptor tyrosine kinase (RTK) pathways, including fibroblast growth factor (FGF) and Ras/MAPK signaling. It acts as a regulatory scaffold, fine-tuning cellular responses to growth factors, differentiation, and survival signals.
SPRY1 has dual roles in cancer biology, context-dependent as either a tumor suppressor or promoter. It can inhibit oncogenic pathways by competing for binding sites or destabilizing signaling complexes, yet in some cancers, it enhances cell proliferation and metastasis. Dysregulation of SPRY1 is linked to cancers (e.g., breast, prostate), fibrosis, and developmental disorders, highlighting its therapeutic relevance.
Recombinant SPRY1 protein is produced via heterologous expression systems (e.g., *E. coli*, mammalian cells*) using DNA cloning techniques to ensure proper folding and post-translational modifications. Purification methods (affinity chromatography, tag-based systems) yield high-purity protein for functional studies. Its applications include elucidating SPRY1 interactions with partners (e.g., Raf-1. FGF receptors), screening inhibitors, and exploring its role in disease models.
In research, SPRY1 recombinant protein aids in deciphering its structural-functional relationships and testing hypotheses about its signaling crosstalk, offering potential for targeted therapies in cancer and regenerative medicine.
×
